Shares of Biocon will hog the limelight this week as the company launched a new and cheaper drug to treat ‘metastatic’ breast cancer that aggressively spreads to other parts of the body.

The company said its product would cost about 25 per cent less than the original.

Roche sells the drug in India as Herceptin, which generated 2012 sales worth around Rs 130 crore. Globally, it was around $6.4 billion. Biocon’s tumour-targeting product is slated to enter the market in the first week of February. It will make breast cancer treatment more affordable and accessible to many Indian patients who test positive for the cancer-indicating HER2 (short for human epidermal growth factor), Chairman and Managing Director Kiran Mazumdar-Shaw told a news conference.

(This article was published on January 19, 2014)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.